NCT01557660View on ClinicalTrials.gov

Inhaled Treprostinil for PAH: Open-label Extension

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2012

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

inhaled treprostinil

0.6mg/mL inhalation solution, up to 12 breaths four times a day

Sponsors
All Listed Sponsors
lead

United Therapeutics

INDUSTRY

NCT01557660 - Inhaled Treprostinil for PAH: Open-label Extension | Biotech Hunter | Biotech Hunter